News
-
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate
BioNxt Solutions Inc. announces GMP manufacturing of Cladribine films & European CTA submission for MS drug candidate BNT23001, advancing toward human clinical study and comparative bioequivalence evaluation -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
BioNxt Solutions Inc. announces the advancement of its sublingual Everolimus oral dissolvable film program targeting organ transplantation, with a comparative pharmacokinetic study -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Advances Cladribine Clinical Program for MS with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
BioNxt Solutions Inc. announces completion of the Investigational Medicinal Product Dossier (IMPD) for BNT23001, their proprietary sublingual cladribine oral dissolvable film product for multiple sclerosis. Key regulatory milestone achieved -
